Two of the reasons why glioblastoma multiforme (GBM) has proven one of the toughest cancers in oncology – being incurable, invariably fatal and with a median overall survival (OS) of two years or less – are its heterogeneity in terms of antigen expression and the difficulty of getting drugs across the blood-brain barrier. But Mustang Bio Inc.’s CAR-T cell therapy MB-101 has managed to get past both hurdles to achieve a significant improvement in OS among patients with recurrent GBM.
Mustang Bio’s MB-101 Gallops To Win In Glioblastoma
The lead author on the Phase I study told Scrip that in addition to targeting a widely expressed antigen on GBM tumors, the CAR-T also stimulates the body’s immune system.
